2010 was not a year of survival breakthroughs in hematologic malignancies. However, in Hodgkin's disease and multiple myeloma new therapies emerged as the standard of care and nilotinib may be considered the treatment choice for newly diagnosed chronic myeloid leukemia.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/nrclinonc.2010.221 | DOI Listing |
Publication Analysis
Top Keywords
standard care
8
hematology 2010
4
2010 therapies
4
therapies standard
4
care oncology
4
oncology 2010
4
2010 year
4
year survival
4
survival breakthroughs
4
breakthroughs hematologic
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!